[Translation] A multicenter phase II clinical study to compare the efficacy, tolerability and safety of GZR101 injection and GZR33-70 injection in patients with type 2 diabetes who were previously poorly controlled with basal insulin or premixed insulin at least once a day, with or without mealtime insulin before dinner.

主要目的:比较GZR101注射液和GZR33-70注射液的疗效。次要目的:比较GZR101注射液和GZR33-70注射液的疗效、耐受性和安全性。

[Translation]

Primary objective: To compare the efficacy of GZR101 injection and GZR33-70 injection. Secondary objective: To compare the efficacy, tolerability and safety of GZR101 injection and GZR33-70 injection.

Start Date-

Sponsor / Collaborator

Gan & Lee Pharmaceuticals Co., Ltd.

CTR20232521

/ CompletedPhase 2

在口服降糖药控制不佳（A部分）或既往使用基础/预混胰岛素控制不佳（B部分）的2型糖尿病患者中比较GZR101注射液与德谷门冬双胰岛素注射液（诺和佳®）的疗效、耐受性和安全性的多中心II期临床研究

[Translation] A multicenter phase II clinical study to compare the efficacy, tolerability and safety of GZR101 injection and degludec insulin aspart injection (Truojia®) in patients with type 2 diabetes who are poorly controlled by oral hypoglycemic drugs (Part A) or have been poorly controlled with basal/premixed insulin (Part B).

主要目的 A部分：对比GZR101注射液和德谷门冬双胰岛素注射液（诺和佳®）每日注射给药一次治疗16周后的疗效、安全性和耐受性。B部分：对比每日一次GZR101注射液联合每日一次门冬胰岛素和每日两次德谷门冬双胰岛素注射液（诺和佳®）治疗16周后的疗效、安全性和耐受性。次要目的研究GZR101注射液每日注射给药一次，治疗16周的GZR33（GZR101成分之一，在研超长效基础胰岛素类似物）和门冬胰岛素（GZR101成分之一，已上市速效胰岛素）的药代动力学（PK）特征。

[Translation]

Main objective Part A: To compare the efficacy, safety and tolerability of GZR101 injection and insulin degludec aspart injection (Novogam®) after 16 weeks of treatment with once-daily injection. Part B: To compare the efficacy, safety and tolerability of GZR101 injection once daily combined with insulin degludec aspart injection once daily and insulin degludec aspart injection twice daily (Novogam®) after 16 weeks of treatment. Secondary objective To study the pharmacokinetic (PK) characteristics of GZR33 (one of the components of GZR101, an ultra-long-acting basal insulin analog under development) and insulin degludec aspart (one of the components of GZR101, a rapid-acting insulin already on the market) after 16 weeks of treatment with GZR101 injection once daily.

Start Date21 Nov 2023

Sponsor / Collaborator

Gan & Lee Pharmaceuticals Co., Ltd.

NCT04237129

/ CompletedPhase 1

A Glucose Clamp Trial Investigating The Biosimilarity of Gan & Lee Insulin Aspart Injection (Insulin Aspart 100 U/ml) With US and EU Insulin Aspart Comparator Products (NovoLog®/NovoRapid®) in Healthy Male Subjects

Primary objective:
To demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of Gan & Lee Insulin Aspart Injection with both EU-approved NovoRapid® and US-licensed NovoLog® (Reference Products) in healthy male subjects
Secondary objectives:
To compare the PK and PD parameters of the three insulin aspart preparations
To evaluate the single dose safety and local tolerability of the three insulin aspart preparations

Start Date27 Aug 2019

Sponsor / Collaborator

Gan & Lee Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Insulin aspart biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

100 Translational Medicine associated with Insulin aspart biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

100 Patents (Medical) associated with Insulin aspart biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

100 Deals associated with Insulin aspart biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A10AD05 A10AB05	DB01306

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	KZ	Gan & Lee Pharmaceuticals Co., Ltd.	26 Aug 2022
Diabetes Mellitus, Type 1	CN	Gan & Lee Pharmaceuticals Co., Ltd.	05 Jun 2020
Diabetes Mellitus, Type 2	CN	Gan & Lee Pharmaceuticals Co., Ltd.	05 Jun 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	NDA/BLA	US	Gan & Lee Pharmaceuticals Co., Ltd.	14 Jun 2023
Diabetes Mellitus, Type 1	Phase 3	CN	-	31 Oct 2013
Diabetes Mellitus, Type 2	Phase 3	CN	-	31 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis